Capital Initiative

Capital Initiative, founded in 1998, is a provider of alternative financing services aimed at supporting small and medium enterprises in France. Originally established to assist entrepreneurs who struggled to secure bank financing, the company has evolved to include consulting and research services alongside its investment activities. Capital Initiative facilitates financing by purchasing and leasing assets from businesses, allowing these companies to retain usage of the assets while generating cash flow. This approach helps businesses meet their working capital needs and supports their growth and development within the region. With a network of approximately 300 associates, Capital Initiative is dedicated to fostering healthy economic growth in the communities it serves.

René Hans

Founder and President

Christian Roellinger

Associate Director

4 past transactions

Endosense

Series C in 2012

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCathÂ® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

Xigen

Series A in 2005

Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade's research expertise on intracellular peptides and signalling.

Addex Therapeutics

Series B in 2004

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Dartfish

Venture Round in 2002

Dartfish develops online and offline video solutions for coaches, athletes, pros, students, teachers, healthcare, and sports organizations. It makes the power of video accessible to millions and sets the video standard across industries such as sport, education, and healthcare. Dartfish also develops cutting-edge online and offline video solutions that empower its users to create, enrich, publish and monetize video content. They received an Emmy Award, IST Price, and Tabby Award 2013 Winner. Dartfish was founded in 1999 and is headquartered in Fribourg, Switzerland with offices in Australia, USA, Sweden, Russia, France, India, Germany, Ireland, Japan, Czech Republic, Korea, and Bahrain.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.